Clinical trial
A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B in the North America and Europe Regions
NCT07654283 is registered in ClinicalTrials.gov with AusperBio Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B in the North America and Europe Regions
- Lead sponsor
- AusperBio Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 1, 2026
- Completion date
- July 26, 2028
- Enrollment
- 70 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.